The safety and glycolipid metabolism efficacy of plant extract essence in obese patients with type 2 diabetes mellitu

The safety and glycolipid metabolism efficacy of plant extract essence in obese patients with type 2 diabetes mellitu - SAGMEP2

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000030869

Enrollment

Registered

2018-01-18

Start date

2018-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type2 diabetes mellitus

Interventions

Orally given eight tablet of Metabarrier premium S(R) daily for three months.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Type 2 diabetes mellitus, BMI >25, HbA1c => 6.5% 2. Patients with normal liver and kidney function 3. Patients who do not take alpha-glucosidase inhibitors 4. Patients who can provide their written consent for participation of this study

Exclusion criteria

Exclusion criteria: 1.Patients with history of drug allergies or food allergies 2.Patients who take glycometabolism, lipid metabolism or blood pressure improvement supplements 3. Patients who take alpha-glucosidase inhibitors 4.Patients with high consumption of alcohol and a history of heavy smoking. 5. Patients with irregular eating patternsintake 6.Women with during pregnancy , nursing, or pregnant likelihood 7.Inadequte patient judged by doctor 8.Unable to obtain informed consent to this study

Design outcomes

Primary

Measure	Time frame
Safety	—

Secondary

Measure	Time frame
Improvement of lipid metabolism	—

Countries

Japan

Contacts

Public ContactKeiko Ogawa

Kanazawa University Hospital Japanese-Traditional (Kampo) Medicine

okeiko@med.kanazawa-u.ac.jp076-265-2918

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026